Latest C-peptide Stories
WALTHAM, Massachusetts and LELYSTAD, The Netherlands, January 3, 2011 /PRNewswire/ -- Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration.
JERUSALEM, November 15, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial.
CRANBURY, N.J., Nov. 2, 2010 /PRNewswire/ -- Palatin Technologies, Inc.
A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies.
SAN MATEO, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that Michael R. Bristow, M.D. Ph.D.
SAN MATEO, Calif., Sept. 9 /PRNewswire/ -- Nile Therapeutics, Inc.
SAN FRANCISCO, July 22 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced the appointment of Richard B. Brewer as Executive Chairman.
NEENAH, Wis., July 21 /PRNewswire/ -- A scientific journal, Phytotherapy Research (May 17, 2010), has reported findings from research teams at King's College London and at Burdwan Medical College, J. B. Ayurved College and Calcutta University (West Bengal).
ORLANDO, Fla., June 28 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes.
- a study of the individuals in a group of people within a specific context and their relationships.
- In rhetoric, the description of any one's personal appearance.